Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
PCSK1N / PROSAAS Antibody (aa182-193)
Goat Polyclonal Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application 
| IHC-P, E |
|---|---|
| Primary Accession | Q9UHG2 |
| Reactivity | Human, Monkey |
| Host | Goat |
| Clonality | Polyclonal |
| Calculated MW | 27kDa |
| Dilution | ELISA (1:1000), IHC-P (5 µg/ml), |
| Gene ID | 27344 |
|---|---|
| Other Names | ProSAAS, Proprotein convertase subtilisin/kexin type 1 inhibitor, Proprotein convertase 1 inhibitor, pro-SAAS, KEP, Big SAAS, b-SAAS, Little SAAS, l-SAAS, N-proSAAS, Big PEN-LEN, b-PEN-LEN, SAAS CT(1-49), PEN, Little LEN, l-LEN, Big LEN, b-LEN, SAAS CT(25-40), PCSK1N |
| Target/Specificity | Human PCSK1N / PROSAAS. |
| Reconstitution & Storage | Store at -20°C. Minimize freezing and thawing. |
| Precautions | PCSK1N / PROSAAS Antibody (aa182-193) is for research use only and not for use in diagnostic or therapeutic procedures. |
| Name | PCSK1N |
|---|---|
| Function | May function in the control of the neuroendocrine secretory pathway. Proposed be a specific endogenous inhibitor of PCSK1. ProSAAS and Big PEN-LEN, both containing the C-terminal inhibitory domain, but not the further processed peptides reduce PCSK1 activity in the endoplasmic reticulum and Golgi. It reduces the activity of the 84 kDa form but not the autocatalytically derived 66 kDa form of PCSK1. Subsequent processing of proSAAS may eliminate the inhibition. Slows down convertase-mediated processing of proopiomelanocortin and proenkephalin. May control the intracellular timing of PCSK1 rather than its total level of activity (By similarity). |
| Cellular Location | Secreted {ECO:0000250|UniProtKB:Q9QXV0}. Golgi apparatus, trans-Golgi network {ECO:0000250|UniProtKB:Q9QXV0}. Note=A N-terminal processed peptide, probably Big SAAS or Little SAAS, is accumulated in cytoplasmic protein tau deposits in frontotemporal dementia and parkinsonism linked to chromosome 17 (Pick disease), Alzheimer disease and amyotrophic lateral sclerosis- parkinsonism/dementia complex 1 (Guam disease) |
| Tissue Location | Expressed in brain and pancreas. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
May function in the control of the neuroendocrine secretory pathway. Proposed be a specific endogenous inhibitor of PCSK1. ProSAAS and Big PEN-LEN, both containing the C-terminal inhibitory domain, but not the further processed peptides reduce PCSK1 activity in the endoplasmic reticulum and Golgi. It reduces the activity of the 84 kDa form but not the autocatalytically derived 66 kDa form of PCSK1. Subsequent processing of proSAAS may eliminate the inhibition. Slows down convertase-mediated processing of proopiomelanocortin and proenkephalin. May control the intracellular timing of PCSK1 rather than its total level of activity. The function of the processed secreted peptides is not known (By similarity).
References
Fricker L.,et al.J. Neurosci. 20:639-648(2000).
Basak A.,et al.J. Biol. Chem. 276:32720-32728(2001).
Kikuchi K.,et al.Biochem. Biophys. Res. Commun. 308:646-654(2003).
Wada M.,et al.Neurosci. Lett. 356:49-52(2004).
Nilsson J.,et al.Nat. Methods 6:809-811(2009).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
